Proximod, a Selective Sphingosine-1-phosphate Receptor 1 Modulator in Patients With Moderate-to-severe Active Rheumatoid Arthritis: a Double-blind, Randomised, Placebo-controlled, Phase 2 Trial.

NCT07335952 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

179

Enrollment

OTHER

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: proximod 5mg daily
DRUG: proximod 10mg daily

Sponsor

Peking University People's Hospital